vs
Side-by-side financial comparison of Jaguar Health, Inc. (JAGX) and SemiLEDs Corp (LEDS). Click either name above to swap in a different company.
Jaguar Health, Inc. is the larger business by last-quarter revenue ($3.2M vs $2.6M, roughly 1.3× SemiLEDs Corp). SemiLEDs Corp runs the higher net margin — -28.9% vs -717.2%, a 688.3% gap on every dollar of revenue. On growth, SemiLEDs Corp posted the faster year-over-year revenue change (103.7% vs -7.8%). Over the past eight quarters, SemiLEDs Corp's revenue compounded faster (70.3% CAGR vs 17.3%).
Jaguar Health, Inc.JAGXEarnings & Financial Report
Jaguar Health, Inc. is a commercial-stage biopharmaceutical firm developing and selling plant-derived prescription medicines for humans and animals. Its products target unmet gastrointestinal treatment needs, with main markets in North America and select European regions, covering human health and animal health segments.
SEMI is an industry association comprising companies involved in the electronics design and manufacturing supply chain. They provide equipment, materials and services for the manufacture of semiconductors, photovoltaic panels, LED and flat panel displays, micro-electromechanical systems (MEMS), printed and flexible electronics, and related micro and nano-technologies.
JAGX vs LEDS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.2M | $2.6M |
| Net Profit | $-23.2M | $-742.0K |
| Gross Margin | 32.0% | 0.7% |
| Operating Margin | -656.6% | -39.4% |
| Net Margin | -717.2% | -28.9% |
| Revenue YoY | -7.8% | 103.7% |
| Net Profit YoY | -133.9% | -35.6% |
| EPS (diluted) | $10.27 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.2M | $2.6M | ||
| Q3 25 | $3.1M | $13.2M | ||
| Q2 25 | $3.0M | $17.7M | ||
| Q1 25 | $2.2M | $10.9M | ||
| Q4 24 | $3.5M | $1.3M | ||
| Q3 24 | $3.1M | $1.3M | ||
| Q2 24 | $2.7M | $1.3M | ||
| Q1 24 | $2.4M | $886.0K |
| Q4 25 | $-23.2M | $-742.0K | ||
| Q3 25 | $-9.5M | $-1.2M | ||
| Q2 25 | $-10.4M | $223.0K | ||
| Q1 25 | $-10.5M | $388.0K | ||
| Q4 24 | $-9.9M | $-547.0K | ||
| Q3 24 | $-9.9M | — | ||
| Q2 24 | $-9.5M | $-319.0K | ||
| Q1 24 | $-9.2M | $-559.0K |
| Q4 25 | 32.0% | 0.7% | ||
| Q3 25 | 82.7% | 1.7% | ||
| Q2 25 | 82.3% | 5.3% | ||
| Q1 25 | 76.7% | 9.2% | ||
| Q4 24 | 84.1% | 20.6% | ||
| Q3 24 | 82.6% | 11.6% | ||
| Q2 24 | 84.3% | 41.0% | ||
| Q1 24 | 81.7% | 12.6% |
| Q4 25 | -656.6% | -39.4% | ||
| Q3 25 | -234.8% | -9.0% | ||
| Q2 25 | -268.8% | -0.4% | ||
| Q1 25 | -425.5% | 1.0% | ||
| Q4 24 | -232.5% | -52.1% | ||
| Q3 24 | -233.7% | — | ||
| Q2 24 | -264.5% | -35.8% | ||
| Q1 24 | -349.4% | -93.9% |
| Q4 25 | -717.2% | -28.9% | ||
| Q3 25 | -308.2% | -9.0% | ||
| Q2 25 | -349.3% | 1.3% | ||
| Q1 25 | -472.6% | 3.6% | ||
| Q4 24 | -282.7% | -43.4% | ||
| Q3 24 | -317.1% | — | ||
| Q2 24 | -348.8% | -24.1% | ||
| Q1 24 | -392.4% | -63.1% |
| Q4 25 | $10.27 | $-0.09 | ||
| Q3 25 | $-6.28 | $-0.15 | ||
| Q2 25 | $-10.26 | $0.03 | ||
| Q1 25 | $-16.70 | $0.05 | ||
| Q4 24 | $-14.62 | $-0.08 | ||
| Q3 24 | $-1.05 | — | ||
| Q2 24 | $-4.04 | $-0.04 | ||
| Q1 24 | $-0.06 | $-0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $968.0K | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-18.7M | $2.1M |
| Total Assets | $38.3M | $14.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $968.0K | $2.9M | ||
| Q3 25 | $3.5M | $2.6M | ||
| Q2 25 | $2.2M | $2.4M | ||
| Q1 25 | $5.7M | $2.4M | ||
| Q4 24 | $8.0M | $1.2M | ||
| Q3 24 | $13.3M | $1.7M | ||
| Q2 24 | $16.0M | $1.7M | ||
| Q1 24 | $11.7M | $1.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | $1.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $3.7M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-18.7M | $2.1M | ||
| Q3 25 | $4.4M | $2.8M | ||
| Q2 25 | $6.9M | $4.0M | ||
| Q1 25 | $830.0K | $3.6M | ||
| Q4 24 | $6.5M | $1.6M | ||
| Q3 24 | $13.1M | $2.2M | ||
| Q2 24 | $16.6M | $2.7M | ||
| Q1 24 | $11.8M | $3.0M |
| Q4 25 | $38.3M | $14.2M | ||
| Q3 25 | $49.5M | $15.6M | ||
| Q2 25 | $48.3M | $23.2M | ||
| Q1 25 | $51.5M | $23.2M | ||
| Q4 24 | $53.4M | $10.4M | ||
| Q3 24 | $58.5M | $11.1M | ||
| Q2 24 | $61.5M | $11.5M | ||
| Q1 24 | $55.4M | $12.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.61× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.5M | $361.0K |
| Free Cash FlowOCF − Capex | — | $331.0K |
| FCF MarginFCF / Revenue | — | 12.9% |
| Capex IntensityCapex / Revenue | — | 1.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.5M | $361.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $693.0K | ||
| Q1 25 | $-7.3M | $1.4M | ||
| Q4 24 | $-7.8M | $-158.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $109.0K | ||
| Q1 24 | $-7.0M | $-600.0K |
| Q4 25 | — | $331.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $383.0K | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $-276.0K | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $98.0K | ||
| Q1 24 | — | $-619.0K |
| Q4 25 | — | 12.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 11.8% | ||
| Q4 24 | — | -21.9% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 7.4% | ||
| Q1 24 | — | -69.9% |
| Q4 25 | — | 1.2% | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.1% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 9.3% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 2.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.11× | ||
| Q1 25 | — | 3.62× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAGX
| Human Health Segment | $3.2M | 97% |
| Other | $83.0K | 3% |
LEDS
Segment breakdown not available.
